Annovis Bio Inc. has hired Hui Liu as its new Director of Biostatistics, a strategic appointment that bolsters the company's scientific capabilities in neurodegenerative disease research. With over 19 years of experience in clinical trial design and analysis, Liu is expected to play a critical role in advancing the company's Phase 3 Alzheimer's disease trial.
Liu's expertise spans multiple therapeutic areas and includes significant experience in clinical trial design, data analysis, and regulatory submission support. The appointment underscores Annovis Bio's commitment to maintaining high scientific standards and developing innovative therapies for neurological disorders.
The addition of Liu to the team signals a focused approach to enhancing the company's research methodology. Her extensive background will be crucial in reinforcing the scientific integrity of Annovis Bio's data and refining regulatory strategies as the company pursues transformative treatments for neurodegenerative conditions like Alzheimer's and Parkinson's.
By bringing in a seasoned biostatistics professional, Annovis Bio demonstrates its dedication to rigorous research and potentially breakthrough therapies that could improve patient outcomes. Liu's role will be pivotal in analyzing complex clinical trial data and supporting the company's goal of developing targeted interventions for neurodegenerative diseases.
